Drug Interaction Report
2 potential interactions and/or warnings found for the following 2 drugs:
- strontium-89 chloride
- Virt Advance (multivitamin, prenatal)
Interactions between your drugs
multivitamin, prenatal strontium-89 chloride
Applies to: Virt Advance (multivitamin, prenatal), strontium-89 chloride
ADJUST DOSING INTERVAL: Saturation of bone-binding sites by calcium may reduce uptake of strontium-89 chloride.
MANAGEMENT: Calcium-containing preparations should be withheld for 2 weeks before until 2 weeks after administration of strontium-89 chloride.
References (1)
- Cerner Multum, Inc. "Australian Product Information."
Drug and food interactions
multivitamin, prenatal food
Applies to: Virt Advance (multivitamin, prenatal)
ADJUST DOSING INTERVAL: Concomitant use of some oral medications may reduce the bioavailability of orally administered iron, and vice versa.
Food taken in conjunction with oral iron supplements may reduce the bioavailability of the iron. However, in many patients intolerable gastrointestinal side effects occur necessitating administration with food.
MANAGEMENT: Ideally, iron products should be taken on an empty stomach (i.e., at least 1 hour before or 2 hours after meals), but if this is not possible, administer with meals and monitor the patient more closely for a subtherapeutic effect. Some studies suggest administration of iron with ascorbic acid may enhance bioavailability. In addition, administration of oral iron products and some oral medications should be separated whenever the bioavailability of either agent may be decreased. Consult the product labeling for specific separation times and monitor clinical responses as appropriate.
References (2)
- "Product Information. Feosol (ferrous sulfate)." SmithKline Beecham
- (2021) "Product Information. Accrufer (ferric maltol)." Shield Therapeutics
Therapeutic duplication warnings
No duplication warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
See also:
Lutathera
Lutathera is a targeted radiotherapy used for gastroenteropancreatic neuroendocrine tumors ...
Ozempic
Learn about Ozempic (semaglutide) for type 2 diabetes treatment, weight management, cardiovascular ...
Pluvicto
Pluvicto (lutetium lu 177 vipivotide tetraxetan) is used for PSMA-positive metastatic ...
Xofigo
XOFIGO radium 223 treatment is a radioactive substance used to treat advanced prostate cancer ...
Sodium iodide-i-131
Sodium iodide-i-131 systemic is used for diagnosis and investigation, hyperthyroidism, thyroid cancer
Radium 223 dichloride
Radium 223 dichloride systemic is used for prostate cancer
Lutetium lu 177 vipivotide tetraxetan
Lutetium lu 177 vipivotide tetraxetan systemic is used for prostate cancer
Learn more
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.